Info: 120 Vegi-Caps (500 mg)
N-Acetyl-L-Carnitine (ALCAR) is an acetylated form of L-carnitine and has the ability to cross the blood-brain barrier, which may supply the body with a more bioavailable form of L-carnitine.
Info: 120 Vegi-Caps (500 mg)
N-Acetyl-L-Carnitine (ALCAR) is an acetylated form of L-carnitine and has the ability to cross the blood-brain barrier, which may supply the body with a more bioavailable form of L-carnitine.
Product Notes:
L-carnitine, an amino acid, aids in the breakdown of long-chain fatty acids and production of cellular energy, but some adults – especially those with a vegetarian or vegan diet – have difficulty maintaining a healthy intake since L-carnitine is primarily found in red meats.
Studies conducted have shown positive results in the improvement of mental function, energy levels, and depressive symptoms in elderly people who have taken ALCAR or in those taking the supplement while battling conditions such as liver and kidney disease or chronic fatigue. ALCAR may also help with cognitive function in young and middle-aged adults. In addition, since ALCAR is broken down to L-carnitine in the body, it may also aid in weight loss, as L-carnitine is needed in order to properly metabolize fats, sugars, and carbohydrates. Some researchers also recommend it as an adjunctive therapy for COPD (Chronic Obstructive Pulmonary Disease), or for reducing peripheral neuropathic pain (PNP) associated with diabetes and certain other conditions.
Related Product: See AOR L-Carnitine.
Health Canada Natural Product Number: 80039706.
AOR ALCAR Ingredients:
Each capsule contains:
500 mg N-Acetyl-L-Carnitine (HCl)
Non-medicinal ingredients: microcrystalline cellulose, silicon dioxide, hypromellose (capsule).
Vegan. Non-GMO. Gluten-Free. Part of AOR's Premium series, ALCAR does not contain wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish, or any animal byproduct.
Suggested Usage:
Take 2 to 4 capsules daily with food, or as directed by a healthcare practitioner. A minimum of three months may be required before observing an effect.
Warnings:
This product provides 1.59 g of a single amino acid per day. Consult a healthcare practitioner prior to use if you are pregnant or breastfeeding, have liver or kidney disease, have been instructed to follow a low protein diet, if symptoms persist or worsen or for use beyond 6 months. Feelings of overstimulation and/or sleeplessness may occur, in which case discontinue use if symptoms persist or worsen.
Low incidence of seizures has been reported with oral doses in individuals with or without a pre-existing seizure disorder. Mild gastrointestinal symptoms (transient nausea, vomiting, abdominal cramps and diarrhea) have been reported. Body odor, flatulence, increased appetite or rash may occur.
Supporting Science:
Hoang, Ba X et al. “Targeting Skeletal Muscle Dysfunction With L-Carnitine for the Treatment of Patients With Chronic Obstructive Pulmonary Disease.” In Vivo (Athens, Greece), 2023.
Li, Sheyu et al. “Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials.” PloS one, 2015.
Montgomery SA, et al. “Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.” International Clinical Psychopharmacology, 2003.
Pooyandjoo, M et al. “The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials.” Obesity Reviews: An official journal of the International Association for the Study of Obesity, 2016.
Verma, Nisha et al. “Ameliorative Effect of Acetyl L-carnitine in Alzheimer's Disease via Downregulating of Homocysteine Levels in Hyperhomocysteinemia Induced Cognitive Deficit in Mouse Model.” Drug Metabolism Letters, 2021.
Veronese, Nicola et al. “Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis.” Psychosomatic Medicine, 2018.